Somatic profile
NeoPainel Somático analyzes sequence variants, copy number and DNA fusions in 560 cancer-associated genes, plus TMB and MSI, in tumor tissue.
See the 560 genes360 Tumor, heredity and medications
Neo360: integrated precision oncology.
Brings together, in a single report, the molecular profile of the tumor, hereditary cancer predisposition and pharmacogenomics of anticancer drugs and supportive care.
See the three modules- Accepted samples
- Peripheral blood (preferred), Buccal swab, Tumor tissue in paraffin (FFPE) (preferred), Extracted DNA
- Turnaround time and when it starts
- 15 calendar days, after acceptance of the sample
- Medical order
- Required. View requirements and limitations.
Clinical scope
Three modules, each with its own question.
The tumor profile, hereditary risk and drug response are answered by different analyses and presented in separate parts of the report, each with its methodology and limitations.
Hereditary cancer predisposition
The Super Painel Cancer germline module assesses 106 genes associated with hereditary cancer syndromes, from whole-genome sequencing.
See the 106 genesPharmacogenomics in oncology
CYP2C19, CYP2D6, DPYD, NUDT15, TPMT and UGT1A1, with recommendations for anticancer drugs and supportive care medications.
Integrated view
Why bring the three modules together.
The result should be interpreted by the treating physician together with clinical and histopathological data. Therapy selection depends on tumor type, current regulatory approvals and clinical judgment.
-
01
The tumor guides therapy
Somatic alterations, TMB and MSI classified by clinical relevance to support decisions on targeted therapies, immunotherapy and clinical trials.
-
02
Heredity changes family care
Without a normal sample, a variant in the tumor may be germline. The germline module, performed on a non-tumor sample, directly assesses the hereditary predisposition genes.
-
03
Medications in the same context
Genes linked to the metabolism of fluoropyrimidines, irinotecan, thiopurines and tamoxifen, and of supportive medications such as antiemetics, analgesics and antidepressants.
Scope and limits
Two samples, explicit limits.
Two samples: tumor tissue for the somatic profile and a germline sample for the heredity and pharmacogenomics modules.
The analysis considers
Tumor, germline and medications.
- Tumor: paraffin block (FFPE), with the tumor area selected by the pathologist, or DNA extracted from the tumor.
- Germline sample: peripheral blood, buccal swab or extracted DNA.
- Anticancer drugs assessed: fluorouracil, capecitabine, irinotecan, mercaptopurine, thioguanine and tamoxifen.
- Supportive care: ondansetron, tropisetron, codeine, amitriptyline, nortriptyline and paroxetine.
Important limitations
Each module has its own limits.
- Somatic profile: analysis restricted to the regions captured by the panel; variants at low allele frequency or in samples with low tumor fraction may not be identified.
- Germline module: repetitive, high-homology or insufficiently covered regions may not be adequately analyzed.
Choice of test
NeoPainel Somático or Neo360?
Both analyze the tumor with the same 560-gene panel. Neo360 adds hereditary cancer predisposition and pharmacogenomics in an integrated report.
| Feature | Neo360 | NeoPainel Somático |
|---|---|---|
| Samples | Tumor and germline sample: blood, buccal swab or DNA | Tumor: paraffin block (FFPE) or extracted DNA |
| Somatic tumor profile | 560 genes, TMB and MSI | 560 genes, TMB and MSI |
| Hereditary cancer predisposition | 106 genes, from whole-genome sequencing | Not included |
| Pharmacogenomics | 6 genes and 12 drugs | Not included |
| Report | Integrated report in three parts | Somatic tumor profile |
- Samples
- NeoPainel SomáticoTumor: paraffin block (FFPE) or extracted DNA
- Neo360Tumor and germline sample: blood, buccal swab or DNA
- Somatic tumor profile
- NeoPainel Somático560 genes, TMB and MSI
- Neo360560 genes, TMB and MSI
- Hereditary cancer predisposition
- NeoPainel SomáticoNot included
- Neo360106 genes, from whole-genome sequencing
- Pharmacogenomics
- NeoPainel SomáticoNot included
- Neo3606 genes and 12 drugs
- Report
- NeoPainel SomáticoSomatic tumor profile
- Neo360Integrated report in three parts
Why germline analysis matters: without a matched normal sample, a variant found in the tumor may be germline. Variants with an allele frequency near 50% or 100% in hereditary predisposition genes should be confirmed in a non-tumor sample, with genetic counseling. Neo360 includes this analysis for 106 hereditary cancer genes.
Follow-up after your results
Infinity VUS
All NeoGenomica tests include Infinity VUS to follow reported variants of uncertain significance. When a relevant reclassification is confirmed after specialist review, the doctor is notified and the report may be updated.
Understand results and Infinity VUSTesting process
From two samples to an integrated report.
One order coordinates the analysis of the tumor and the germline sample.
-
01
Medical order
Tumor type, clinical data, family history and current medications guide the analysis.
-
02
Tumor sample
Paraffin block with the tumor area selected by the pathologist, or DNA extracted from the tumor.
-
03
Germline sample
Peripheral blood, buccal swab or extracted DNA for the heredity and pharmacogenomics modules.
-
04
Analyses
Somatic panel on the tumor and whole genome on the germline sample.
-
05
Integrated report
Three parts, each with its findings, methodology and limitations.
Frequently asked questions
Before ordering Neo360.
What is the difference between Neo360 and NeoPainel Somático?
NeoPainel Somático analyzes only the tumor. Neo360 includes the same somatic profile and adds hereditary cancer predisposition, across 106 genes, and pharmacogenomics in an integrated report.
Which samples are needed?
Two samples: a paraffin block (FFPE) with tumor tissue, or DNA extracted from the tumor, for the somatic profile; and peripheral blood, a buccal swab or extracted DNA for the germline and pharmacogenomics modules.
Is the germline result relevant to the family?
It may be. Germline variants may be present in relatives, and the report includes information relevant to them. Discussion with genetic counseling is recommended when there is a germline finding.
Does pharmacogenomics define the treatment dose?
Not on its own. The result complements clinical assessment, and cancer medications should not be changed based on the test alone.
When will the report be ready?
15 calendar days, after acceptance of the sample .
Does the test require a medical request?
Yes. The tumor type, clinical and histopathological data, family history and current medications guide the analysis and interpretation.
Next step
Discuss the case with our team.
We provide guidance on the samples, documentation and limits of each Neo360 module before shipment.
Test information
Technical details for Neo360
Method, scope, requirements and limitations
Integrated precision oncology: molecular tumor profile, hereditary cancer predisposition and pharmacogenomics in a single report.
- Applications
- Hereditary cancer, Precision oncology, Pharmacogenomics
- Accepted samples
- Peripheral blood (preferred), Buccal swab, Tumor tissue in paraffin (FFPE) (preferred), Extracted DNA
- Estimated turnaround time
- 15 calendar days, after acceptance of the sample
- Methodology
- Somatic module: next-generation sequencing (NGS) of DNA with hybrid capture using the Twist Oncology DNA CGP panel and bioinformatic analysis with the NeoSoma pipeline, identifying and annotating SNVs, small insertions and deletions, copy number alterations, rearrangements and fusions predicted in DNA, TMB and MSI. Germline module: whole-genome sequencing (WGS) with a curated panel of 106 risk genes. Pharmacogenomics: analysis from the whole-genome data, with variant interpretation using the PyPGx tool, PharmGKB and CPIC guidelines.
- Analytical scope
- Somatic profile: 560 cancer-associated genes, with SNVs, indels and multinucleotide variants, copy number alterations, DNA fusions and rearrangements, TMB and MSI. Hereditary predisposition: 106 genes associated with hereditary cancer syndromes. Pharmacogenomics: CYP2C19, CYP2D6, DPYD, NUDT15, TPMT and UGT1A1, with recommendations for 12 drugs across anticancer therapy and supportive care.
- Medical order
- Required
Requirements
Medical order with the tumor type, clinical and histopathological information, personal and family history and current medications. Two samples: a paraffin block (FFPE) with tumor tissue, with the tumor area selected by the pathologist, or DNA extracted from the tumor, for the somatic module; and peripheral blood, a buccal swab or extracted DNA for the germline and pharmacogenomics modules.
Limitations
Somatic module: analysis restricted to the regions captured by the panel. Variants at low allele frequency, below the limit of detection or in samples with low tumor fraction may not be identified. Fusions and rearrangements are assessed in DNA, only in the captured intronic regions. TMB and MSI are panel-based estimates and are not directly interchangeable with those of other methods. Germline module: repetitive, high-homology or insufficiently covered or low-quality regions may not be adequately sequenced or analyzed. Pharmacogenomics: metabolizer phenotypes are inferences based on known variants and may not capture all genetic or environmental influences or drug interactions.
Additional information
Each module is presented in its own part of the report, with methodology and limitations. Missing data for a module is not equivalent to a negative result. Cancer medications should not be changed based on pharmacogenomics alone. Infinity VUS is included for variants of uncertain significance reported in the germline module.
